Skip to main content
EnglishEN
European Commission logo print header

Next generation advanced RNA inhibition therapy to treat cardiometabolic disease

Project description

DEENESFRITPL

RNA therapeutics for cardiometabolic diseases

Cardiometabolic diseases include diabetes, non-alcoholic fatty liver disease and atherosclerotic cardiovascular disease. Although these diseases frequently co-exist in patients, interventions have yet to be designed against their common targets and shared pathways. The EU-funded LiverTarget project brings together worldwide experts in the field to develop and test innovative therapies against such cardiometabolic diseases. Researchers will focus on ribonucleic acid (RNA) therapeutics such as small interfering RNA to silence the expression of inflammatory genes in the liver. These RNA molecules will be complexed with lipid nanoparticles for effective delivery to the liver, tested in preclinical mouse models for efficacy, and the lead candidates evaluated.

Objective

RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that have attracted tremendous interest recently due to their first in-class drug approvals and notable success of the mRNA vaccines in the clinic.

Obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), in turn, are highly prevalent devastating diseases of our times despite available medicines, accounting for more than one in two deaths worldwide. They frequently co-exist, in the same patient, and constitute independent risk factors for each other; yet, unified approaches directed against common targets and shared mechanisms are lacking.

LiverTarget aims at exploiting Partners years of research in the field of cardiometabolic research, the identification of ceramide pathways and inflammatory targets, and the development of novel siRNA technologies and lipid formulations, to:

1. Generate innovative siRNA pools and synthetic mRNAs to regulate ceramide and inflammatory targets in the liver.
2. Formulate them in established human-approved liver-targeting lipid nanoparticles (LNP).
3. Determine their efficacy in vivo in preclinical mouse models of obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and atherosclerosis.
4. Complete the necessary safety and toxicology evaluation of the most promising lead candidates and prepare the preclinical evaluation dossier for the European Medicines Agency (EMA).

This will result in a set of novel RNA-LNP formulations, directed against targets shared between ASCVD, diabetes and NAFLD, with demonstrated efficacy and toxicology, ready for further clinical development. It will also open up new directions of research towards the development innovative RNA therapeutics against liver targets for the treatment of cardiometabolic diseases, ultimately benefiting the patient, the society and the economy.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

HORIZON-HLTH-2021-TOOL-06

See other projects for this call

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

Coordinator

TAMPEREEN KORKEAKOULUSAATIO SR
Net EU contribution
€ 2 018 750,00
Address
KALEVANTIE 4
33100 Tampere
Finland

See on map
Region
Manner-Suomi Länsi-Suomi Pirkanmaa
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 018 750,00

Participants (8)

Share this page

Download

Last update: 28 July 2022

My Booklet

Permalink: https://cordis.europa.eu/project/id/101057724

European Union, 2024